false
0001739104
Elanco Animal Health Incorporated
0001739104
2026-01-12
2026-01-12
0001739104
us-gaap:CommonStockMember
2026-01-12
2026-01-12
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
January 12, 2026
Elanco
Animal Health Incorporated
(Exact name of registrant as specified in its
charter)
| Indiana | |
001-38661 | |
82-5497352 |
(State
or other jurisdiction
of incorporation) | |
(Commission
File Number) | |
(I.R.S.
Employer Identification
No.) |
450
Elanco Circle
Indianapolis,
Indiana (Address
of principal executive offices)
| |
46222 (Zip
Code) |
Registrant’s telephone number, including
area code: (877) 352-6261
Not Applicable
(Former Name or Address, if Changed Since Last
Report)
Check the appropriate
box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
| ¨ | Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each
class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which
registered |
| Common
stock, no par value |
|
ELAN |
|
New
York Stock Exchange |
Indicate by check
mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this
chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
¨ Emerging
growth company
If an emerging growth
company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
On January 13, 2026,
Elanco Animal Health Incorporated (the “Company”) will present at the 44th Annual J.P. Morgan Healthcare Conference (the
“JPM Conference”). A copy of the Company’s JPM Conference presentation is furnished as Exhibit 99.1.
The information in this Item
7.01, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of
Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities
of that Section and shall not be incorporated by reference into any registration statement or other document pursuant to the Securities
Act of 1933, as amended, or the Exchange Act, except as otherwise expressly stated in such filing.
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits
| Exhibit No. |
|
Description |
| |
|
|
| 99.1 |
|
Investor
Presentation of Elanco Animal Health Incorporated at the JPM Conference. |
| 104.1 |
|
Cover
Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| |
Elanco Animal
Health Incorporated |
| |
|
|
| Date: January 12, 2026 |
By: |
/s/
Robert M. VanHimbergen |
| |
|
Name: Robert M. VanHimbergen |
| |
|
Title: Executive Vice President,
Chief Financial Officer |
